Key Information Document

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

You are about to purchase a product that is not simple and may be difficult to understand

Product

Name: Aescap Genetics - Manager ISIN code: NL0015000QA5 Name of PRIIP Manufacturer: Privium Fund Management B.V. Contact details: <u>www.priviumfund.com</u> and <u>www.aescap.com</u> Competent authority: Privium Fund Management B.V. is authorised and regulated by the Dutch Authority for the Financial Markets (AFM) Date of production of this document: 12 January 2022

What is this product?


Type: The Fund is a fund for joint account (in Dutch: een fonds voor gemene rekening). It does not have a legal personality. It is formed by and comprises a contractual arrangement governed by the terms of the Prospectus between the Fund Manager, the Legal Owner and each Unit Holder.

Objectives: The Fund invests in the shares of publicly listed genetics biotech / life sciences companies. It invests in highly innovative companies that develop and market new genetics medical treatments such as gene, RNA and cell therapies. The Fund has a focused portfolio, investing in approximately 15 companies. Within this focus it will ensure that the portfolio is diversified over different diseases, development phases and geographical areas. The Fund's objective is to make an average minimum annual net return (after deduction of costs) of 20%+ over the mid-term (4-5 years).

Intended retail investor: A Well-Informed investor who either invests a minimum of EUR 100,000 (one hundred thousand Euro) in the Fund. The investment horizon of an investor is at least 5 years and an investor understand the risk of losing some or all of the capital invested. The minimum investment horizon is in line with the objective and investment strategy of the Fund. The investor understands the characteristics and risks associated with investing in the Fund. The Fund promotes social characteristics. In the context of the EU Sustainable Finance Disclosure Regulation (SFDR), the Fund is therefore classified as an Article 8 fund.

Maturity: The term is unlimited.

What are the risks and what could I get in return?



Performance scenarios	Investment EUR 10,000 Scenarios		1 year	3 years	5 years (recommended holding period)
	Stress scenario	What you might get back after costs	EUR 4,871	EUR 4,064	EUR 2,990
		Average return each year	-51.3%	-25.9%	-21.5%
	Unfavourable scenario	What you might get back after costs	EUR 8,378	EUR 8,441	EUR 9,080
		Average return each year	-16.2%	-5.5%	-1.9%
	Moderate scenario	What you might get back after costs	EUR 11,121	EUR 13,286	EUR 17,190
		Average return each year	11.2%	11.4%	11.4%
	Favourable scenario	What you might get back after costs	EUR 14,890	EUR 22,842	EUR 32,823
		Average return each year	48.9%	31.7%	26.8%
	scenarios of other pro The scenarios prese how the value of this on how the market pro The stress scenario s take into account the The figure shown inc	nted are an estimate investment varies, and erforms and how long shows what you migh situation where we a lude all the costs of th tributor. The figures do	of future performa d are not an exact in you keep the inves t get back in extrer re not able to pay y e product itself, but	nce based on evide ndicator. What you g stment. ne market circumsta you. : may not include all f	nce from the past et will vary dependi inces, and it does r the costs that you p
		Fund Managa		s unable to p	ay out? uct's assets is thus

Costs over time	The person selling you, or advising you, about this product may charge you other costs. If so, this person will provide you with information about these costs, and show you the impact that all costs will have on your investment over time.
	Investment EUR 10,000

	Scenarios	lf you cash year	If you cash in after 1 year		cash in after 3	If you cash in after 5 years (recommended holding period)		
	Total costs	Euro 27		Euro 81		Euro 135		
	Impact on return (F per year	RIY) 0.27%	0.27%			0.27%		
Composition of costs	 The table below shows: The impact each year of the different types of costs on the investment returns you might get at the end of the recommended holding period; and The meaning of the different cost categories This table shows the impact on return per year 							
	One-off costs	Entry costs	0.05% (benefit fund)	for the of the	The impact of the costs you pay when entering your investment.			
		Exit costs		for the of the	The impact of the costs of exiting your investment when it matures.			
	On-going costs	Portfolio transaction costs	0.03%		The impact of the costs of us buying and selling underlying investments for the product.			
		Other ongoing costs	0.27%		The impact of the costs that we take each year for managing your investments.			
	Incidental costs	Performance fees	0%		take these Appreciation, if Fund during t	he performance fee. We from your Net New f any, achieved by the he performance period, h water mark limitation.		
		Carried interests	N/A		The impact of c	arried interests.		

How long should I hold it and can I take money out early?

Recommended holding period: 5 years

Units may only be redeemed on Redemption Dates with due notice. No partial redemptions will be permitted if, immediately thereafter, the value of a redeeming Unit Holder's holding would be less than the minimum holding permitted, unless approved by the Fund Manager in its sole and absolute discretion. Shares may not be redeemed when the calculation of the NAV is suspended.

Investing in biotech companies involves a high degree of risk and prices of the securities of such companies, especially of companies with a small market cap, may be volatile. Furthermore, there is concentration risk because of the genetics biotech focus and a relatively concentrated portfolio. Therefore, a longer term holding period is recommended.

How can I complain?

Should you have a complaint, you can contact Privium Fund Management B.V. by email, telephone or post.

Email: compliants@priviumfund.com Telephone: +31 20 46 26 644 Post: Gustav Mahlerplein 3, 26th floor, Financial Offices, 1082 MS Amsterdam

Other relevant information

We are required to provide you with further documentation, such as the product's latest prospectus and annual reports. These documents and other product information are available online at www.aescap.com